Vikram Purohit has given his Buy rating due to a combination of factors related to Axsome Therapeutics' performance and market potential. The company's drug, Auvelity, has shown a strong initial commercial performance for the treatment of major depressive disorder since its approval in August 2022. Purohit notes that Auvelity has generated approximately $254 million in sales through its initial seven quarters post-launch. This trajectory aligns with the expectations of reaching over $1 billion in sales by 2027, as per consensus estimates, indicating a promising growth outlook for Axsome Therapeutics.